Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: The MYRROR study

Yasushi Ikuno, Kyoko Ohno-Matsui, Tien Yin Wong, Jean Francois Korobelnik, Robert Vitti, Tummy Li, Brigitte Stemper, Friedrich Asmus, Oliver Zeitz, Tatsuro Ishibashi

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Purpose To evaluate intravitreal aflibercept 2 mg in patients with myopic choroidal neovascularization (CNV). Design An international, phase III, multicenter, randomized, double-masked, sham-controlled study. Participants Patients aged ≥18 years with high myopia (≥-6.0 diopters or axial length of ≥26.5 mm), active myopic CNV, and best-corrected visual acuity (BCVA) of 73-35 Early Treatment Diabetic Retinopathy Study letters in the study eye were included. Methods Patients were randomized 3:1 to intravitreal aflibercept or sham. In the intravitreal aflibercept arm, patients received 1 injection at baseline. Additional injections were performed in case of CNV persistence or recurrence at monthly visits through week 44. In the sham arm, patients received sham injections through week 20. At week 24, after assessment of the primary efficacy end point, sham patients received a mandatory intravitreal aflibercept injection followed by intravitreal aflibercept (if disease persisted/recurred) or sham injection every 4 weeks. Main Outcome Measures Mean change in BCVA from baseline to week 24. Results A total of 122 patients were randomized to intravitreal aflibercept (n = 91) or sham (n = 31). Baseline demographics were similar across groups. At week 24, patients in the intravitreal aflibercept and sham groups gained 12.1 and lost 2 letters, respectively (P < 0.0001). By week 48, patients in the intravitreal aflibercept and sham/intravitreal aflibercept groups gained 13.5 and 3.9 letters. Patients in the intravitreal aflibercept group received 2 injections (median) in the first study quarter (week 0-8). Median number of injections in quarters 2 to 4 was 0. Patients in the "sham/intravitreal aflibercept" group received 2 and 1 (median) intravitreal aflibercept injections in quarters 3 and 4. Central retinal thickness improved in parallel with visual gains. Incidence of ocular adverse events was similar in both groups through week 48 (37.4% vs. 38.7); most were assessed by investigators as mild. No deaths occurred. Conclusions Intravitreal aflibercept 2 mg was effective for treatment of myopic CNV with clinically important visual and anatomic benefits achieved with a limited number of injections given in the first 8 weeks of treatment. No new safety concerns occurred with treatment. Intravitreal aflibercept should be considered as a treatment option for myopic CNV.

Original languageEnglish
Pages (from-to)1220-1227
Number of pages8
JournalOphthalmology
Volume122
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Choroidal Neovascularization
Intravitreal Injections
Injections
aflibercept
Visual Acuity
Arm
Therapeutics
Myopia
Diabetic Retinopathy

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Intravitreal aflibercept injection in patients with myopic choroidal neovascularization : The MYRROR study. / Ikuno, Yasushi; Ohno-Matsui, Kyoko; Wong, Tien Yin; Korobelnik, Jean Francois; Vitti, Robert; Li, Tummy; Stemper, Brigitte; Asmus, Friedrich; Zeitz, Oliver; Ishibashi, Tatsuro.

In: Ophthalmology, Vol. 122, No. 6, 01.06.2015, p. 1220-1227.

Research output: Contribution to journalArticle

Ikuno, Y, Ohno-Matsui, K, Wong, TY, Korobelnik, JF, Vitti, R, Li, T, Stemper, B, Asmus, F, Zeitz, O & Ishibashi, T 2015, 'Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: The MYRROR study', Ophthalmology, vol. 122, no. 6, pp. 1220-1227. https://doi.org/10.1016/j.ophtha.2015.01.025
Ikuno, Yasushi ; Ohno-Matsui, Kyoko ; Wong, Tien Yin ; Korobelnik, Jean Francois ; Vitti, Robert ; Li, Tummy ; Stemper, Brigitte ; Asmus, Friedrich ; Zeitz, Oliver ; Ishibashi, Tatsuro. / Intravitreal aflibercept injection in patients with myopic choroidal neovascularization : The MYRROR study. In: Ophthalmology. 2015 ; Vol. 122, No. 6. pp. 1220-1227.
@article{8d92c28767314c9fb59ca9fafd39f73c,
title = "Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: The MYRROR study",
abstract = "Purpose To evaluate intravitreal aflibercept 2 mg in patients with myopic choroidal neovascularization (CNV). Design An international, phase III, multicenter, randomized, double-masked, sham-controlled study. Participants Patients aged ≥18 years with high myopia (≥-6.0 diopters or axial length of ≥26.5 mm), active myopic CNV, and best-corrected visual acuity (BCVA) of 73-35 Early Treatment Diabetic Retinopathy Study letters in the study eye were included. Methods Patients were randomized 3:1 to intravitreal aflibercept or sham. In the intravitreal aflibercept arm, patients received 1 injection at baseline. Additional injections were performed in case of CNV persistence or recurrence at monthly visits through week 44. In the sham arm, patients received sham injections through week 20. At week 24, after assessment of the primary efficacy end point, sham patients received a mandatory intravitreal aflibercept injection followed by intravitreal aflibercept (if disease persisted/recurred) or sham injection every 4 weeks. Main Outcome Measures Mean change in BCVA from baseline to week 24. Results A total of 122 patients were randomized to intravitreal aflibercept (n = 91) or sham (n = 31). Baseline demographics were similar across groups. At week 24, patients in the intravitreal aflibercept and sham groups gained 12.1 and lost 2 letters, respectively (P < 0.0001). By week 48, patients in the intravitreal aflibercept and sham/intravitreal aflibercept groups gained 13.5 and 3.9 letters. Patients in the intravitreal aflibercept group received 2 injections (median) in the first study quarter (week 0-8). Median number of injections in quarters 2 to 4 was 0. Patients in the {"}sham/intravitreal aflibercept{"} group received 2 and 1 (median) intravitreal aflibercept injections in quarters 3 and 4. Central retinal thickness improved in parallel with visual gains. Incidence of ocular adverse events was similar in both groups through week 48 (37.4{\%} vs. 38.7); most were assessed by investigators as mild. No deaths occurred. Conclusions Intravitreal aflibercept 2 mg was effective for treatment of myopic CNV with clinically important visual and anatomic benefits achieved with a limited number of injections given in the first 8 weeks of treatment. No new safety concerns occurred with treatment. Intravitreal aflibercept should be considered as a treatment option for myopic CNV.",
author = "Yasushi Ikuno and Kyoko Ohno-Matsui and Wong, {Tien Yin} and Korobelnik, {Jean Francois} and Robert Vitti and Tummy Li and Brigitte Stemper and Friedrich Asmus and Oliver Zeitz and Tatsuro Ishibashi",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.ophtha.2015.01.025",
language = "English",
volume = "122",
pages = "1220--1227",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Intravitreal aflibercept injection in patients with myopic choroidal neovascularization

T2 - The MYRROR study

AU - Ikuno, Yasushi

AU - Ohno-Matsui, Kyoko

AU - Wong, Tien Yin

AU - Korobelnik, Jean Francois

AU - Vitti, Robert

AU - Li, Tummy

AU - Stemper, Brigitte

AU - Asmus, Friedrich

AU - Zeitz, Oliver

AU - Ishibashi, Tatsuro

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Purpose To evaluate intravitreal aflibercept 2 mg in patients with myopic choroidal neovascularization (CNV). Design An international, phase III, multicenter, randomized, double-masked, sham-controlled study. Participants Patients aged ≥18 years with high myopia (≥-6.0 diopters or axial length of ≥26.5 mm), active myopic CNV, and best-corrected visual acuity (BCVA) of 73-35 Early Treatment Diabetic Retinopathy Study letters in the study eye were included. Methods Patients were randomized 3:1 to intravitreal aflibercept or sham. In the intravitreal aflibercept arm, patients received 1 injection at baseline. Additional injections were performed in case of CNV persistence or recurrence at monthly visits through week 44. In the sham arm, patients received sham injections through week 20. At week 24, after assessment of the primary efficacy end point, sham patients received a mandatory intravitreal aflibercept injection followed by intravitreal aflibercept (if disease persisted/recurred) or sham injection every 4 weeks. Main Outcome Measures Mean change in BCVA from baseline to week 24. Results A total of 122 patients were randomized to intravitreal aflibercept (n = 91) or sham (n = 31). Baseline demographics were similar across groups. At week 24, patients in the intravitreal aflibercept and sham groups gained 12.1 and lost 2 letters, respectively (P < 0.0001). By week 48, patients in the intravitreal aflibercept and sham/intravitreal aflibercept groups gained 13.5 and 3.9 letters. Patients in the intravitreal aflibercept group received 2 injections (median) in the first study quarter (week 0-8). Median number of injections in quarters 2 to 4 was 0. Patients in the "sham/intravitreal aflibercept" group received 2 and 1 (median) intravitreal aflibercept injections in quarters 3 and 4. Central retinal thickness improved in parallel with visual gains. Incidence of ocular adverse events was similar in both groups through week 48 (37.4% vs. 38.7); most were assessed by investigators as mild. No deaths occurred. Conclusions Intravitreal aflibercept 2 mg was effective for treatment of myopic CNV with clinically important visual and anatomic benefits achieved with a limited number of injections given in the first 8 weeks of treatment. No new safety concerns occurred with treatment. Intravitreal aflibercept should be considered as a treatment option for myopic CNV.

AB - Purpose To evaluate intravitreal aflibercept 2 mg in patients with myopic choroidal neovascularization (CNV). Design An international, phase III, multicenter, randomized, double-masked, sham-controlled study. Participants Patients aged ≥18 years with high myopia (≥-6.0 diopters or axial length of ≥26.5 mm), active myopic CNV, and best-corrected visual acuity (BCVA) of 73-35 Early Treatment Diabetic Retinopathy Study letters in the study eye were included. Methods Patients were randomized 3:1 to intravitreal aflibercept or sham. In the intravitreal aflibercept arm, patients received 1 injection at baseline. Additional injections were performed in case of CNV persistence or recurrence at monthly visits through week 44. In the sham arm, patients received sham injections through week 20. At week 24, after assessment of the primary efficacy end point, sham patients received a mandatory intravitreal aflibercept injection followed by intravitreal aflibercept (if disease persisted/recurred) or sham injection every 4 weeks. Main Outcome Measures Mean change in BCVA from baseline to week 24. Results A total of 122 patients were randomized to intravitreal aflibercept (n = 91) or sham (n = 31). Baseline demographics were similar across groups. At week 24, patients in the intravitreal aflibercept and sham groups gained 12.1 and lost 2 letters, respectively (P < 0.0001). By week 48, patients in the intravitreal aflibercept and sham/intravitreal aflibercept groups gained 13.5 and 3.9 letters. Patients in the intravitreal aflibercept group received 2 injections (median) in the first study quarter (week 0-8). Median number of injections in quarters 2 to 4 was 0. Patients in the "sham/intravitreal aflibercept" group received 2 and 1 (median) intravitreal aflibercept injections in quarters 3 and 4. Central retinal thickness improved in parallel with visual gains. Incidence of ocular adverse events was similar in both groups through week 48 (37.4% vs. 38.7); most were assessed by investigators as mild. No deaths occurred. Conclusions Intravitreal aflibercept 2 mg was effective for treatment of myopic CNV with clinically important visual and anatomic benefits achieved with a limited number of injections given in the first 8 weeks of treatment. No new safety concerns occurred with treatment. Intravitreal aflibercept should be considered as a treatment option for myopic CNV.

UR - http://www.scopus.com/inward/record.url?scp=84930039255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930039255&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2015.01.025

DO - 10.1016/j.ophtha.2015.01.025

M3 - Article

C2 - 25745875

AN - SCOPUS:84930039255

VL - 122

SP - 1220

EP - 1227

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 6

ER -